Meeder Asset Management’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-267
Closed -$5.8K 939
2024
Q3
$5.8K Sell
267
-1,391
-84% -$31.1K ﹤0.01% 719
2024
Q2
$32.5K Hold
1,658
﹤0.01% 419
2024
Q1
$36K Buy
+1,658
New +$41.2K ﹤0.01% 408
2023
Q2
Sell
-32,726
Closed -$1.02M 539
2023
Q1
$1.02M Sell
32,726
-6,160
-16% -$198K 0.08% 167
2022
Q4
$1.16M Sell
38,886
-4,578
-11% -$164K 0.1% 179
2022
Q3
$1.66M Buy
43,464
+11,148
+34% +$559K 0.1% 174
2022
Q2
$1.76M Buy
32,316
+6,184
+24% +$340K 0.1% 169
2022
Q1
$1.63M Buy
+26,132
New +$1.72M 0.08% 187
2021
Q4
Sell
-79
Closed -$7K 1584
2021
Q3
$7K Sell
79
-86
-52% -$7.82K ﹤0.01% 1795
2021
Q2
$15K Sell
165
-286
-63% -$22.8K ﹤0.01% 1558
2021
Q1
$44K Buy
451
+433
+2,406% +$44.7K ﹤0.01% 1150
2020
Q4
$1K Sell
18
-1,005
-98% -$42K ﹤0.01% 1644
2020
Q3
$41K Buy
+1,023
New +$32K ﹤0.01% 993
2017
Q2
Sell
-11
Closed 1719
2017
Q1
$0 Buy
+11
New +$130 ﹤0.01% 1679

Other funds holding FLGT

Meeder Asset Management's FLGT Position: Q4 2024 in Review

Meeder Asset Management sold out of Fulgent Genetics (FLGT) in Q4 2024, closing a stake of 267 shares — an estimated $5.8K sold.

Meeder Asset Management first reported a position in FLGT in Q1 2017 and held it in 14 quarters. The position peaked at $1.76M in Q2 2022. 189 funds tracked by Wall St. Rank hold FLGT as of Q4 2024.

  • Meeder Asset Management reported no remaining Fulgent Genetics position as of Q4 2024 after selling out during the quarter.
  • Meeder Asset Management sold 267 Fulgent Genetics shares in Q4 2024, an estimated $5.8K.
  • Meeder Asset Management first reported a position in Fulgent Genetics in Q1 2017 and held it in 14 quarters.
  • Meeder Asset Management's Fulgent Genetics position peaked at $1.76M in Q2 2022.
  • 189 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2024.

Based on Meeder Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.